DB06257ExperimentalSmall molecule
Investigated for use/treatment in adverse effects (chemotherapy), hyperlipidemia, autoimmune diseases, and hepatitis (viral, B).
- Primary indication
- Investigated for use/treatment in adverse effects (chemotherapy), hyperlipidemia, autoimmune diseases, and hepatitis (viral, B).Curator reviewed
- Formula / weight
- C19H30O3 ยท 306.446 g/mol (avg)
- Also known as
- beta-Aet
- Code names
- HE-2200
Resolves to
Compound
Structure
InChIKey
OEVZKEVBDIDVOI-YSZCXEEOSA-NSMILES[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C=C2C[C@@H](O)CC[C@]12CWhich companies are running trials of HE-2200, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account